What the phase 3 trial revealed
- Children with hypochondroplasia receiving daily vosoritide injections achieved an annualized growth velocity gain of 2.33 centimeters per year over placebo after 52 weeks of treatment (P < .0001).
- Total standing height in the treatment group grew by 2.35 centimeters more than in the placebo group, accompanied by a height Z-score improvement of 0.39 standard deviations.
- Arm span increased by 1.03 centimeters more in treated children than in those assigned to placebo over the one-year evaluation period.
- The medication showed a clean safety record with zero grade 3 or higher adverse events, zero treatment dropouts, and zero deaths across 81 enrolled pediatric participants.
| Finding | Plain-English meaning |
|---|---|
| Daily vosoritide increased annualized growth velocity by 2.33 cm per year over placebo | Children taking daily vosoritide grew faster than children receiving a placebo injection over one year. |
| Vosoritide increased total standing height by 2.35 cm relative to placebo | Children on the treatment gained more overall height compared to children given placebo over 52 weeks. |
| Height Z-score improved by 0.39 standard deviations in the vosoritide group | Treated children moved closer to average height ranges for their age and sex. |
| Arm span increased by 1.03 cm more in the vosoritide group than in placebo | The drug helped children’s arm length grow alongside their overall body growth. |
| Zero grade 3 or higher adverse events and zero study dropouts occurred | The trial drug was well tolerated without severe safety issues causing kids to stop treatment. |
Key data from the CANOPY-HCH-3 study
| Trial Metric | Study Value |
|---|---|
| Study Design | Phase 3 randomized, double-blind, placebo-controlled trial (NCT06455059) |
| Total Participants | 81 children (41 vosoritide, 40 placebo) aged 3 to under 18 years |
| Primary Outcome Difference | +2.33 cm/year growth velocity (95% CI, 1.85 to 2.82; P < .0001) |
| Standing Height Improvement | +2.35 cm relative to placebo (P < .05) |
| Arm Span Improvement | +1.03 cm relative to placebo (P < .05) |
| Serious Adverse Events | 0 in vosoritide arm (1 seizure reported in placebo arm) |
| Primary Funder | BioMarin Pharmaceutical Inc. |
Understanding hypochondroplasia and why standard options fall short
Hypochondroplasia is a rare genetic skeletal dysplasia caused by gain-of-function mutations in the fibroblast growth factor receptor 3 (FGFR3) gene. These genetic variants create an overactive signal inside growing cartilage cells, which slows down endochondral ossification, the biological process that converts cartilage into long bones. As a result, children born with hypochondroplasia develop disproportionate short stature, relatively enlarged head size (macrocephaly), shortened limbs, and sometimes neurological issues like infant seizures or developmental delays.
Prevalence estimates for hypochondroplasia range between 0.2 per 100,000 individuals and 1 in 15,000 people. Because the physical features of hypochondroplasia vary widely from mild to moderate short stature, many cases go undiagnosed or are identified late in childhood. BioMarin Pharmaceutical estimates that roughly 14,000 children worldwide fall within its commercial footprint for potential treatment.
Until now, families and pediatricians facing a hypochondroplasia diagnosis had no approved targeted therapies that address the underlying genetic cause. Management has remained limited to supportive care, invasive surgical limb-lengthening procedures, or off-label use of human growth hormone. Recombinant growth hormone holds formal approval for hypochondroplasia only in Japan. Consequently, pediatric endocrinologists have long sought a disease-modifying medicine that restores normal cartilage activity during critical growth years.
How vosoritide targets the cellular brakes on bone growth
Vosoritide, marketed under the brand name Voxzogo for achondroplasia, is a synthetic C-type natriuretic peptide (CNP) analog. In healthy bone development, CNP binds to specific receptors on chondrocytes (cartilage-forming cells) inside the growth plates near the ends of long bones. This binding triggers a chemical cascade that shuts off downstream mitogen-activated protein kinase (MAPK) signaling.
In children with hypochondroplasia, the mutated FGFR3 gene acts like a stuck gas pedal that keeps the MAPK signaling pathway permanently active, putting the brakes on bone growth. Vosoritide steps into this pathway by binding to the CNP receptor, acting like a biological bypass that releases that jammed brake pedal on cartilage maturation.
By suppressing excess MAPK signaling, vosoritide allows chondrocytes to multiply, align, and turn into solid bone structure at a rate closer to typical growth patterns. Investigators verified this precise biological action by tracking serum collagen X levels. Collagen X is a blood biomarker that signals active endochondral bone formation. In the CANOPY-HCH-3 trial, collagen X levels surged in participants receiving daily vosoritide and remained elevated throughout the 52-week study, confirming that the drug maintained targeted bone building over time.
Growth velocity and secondary results in 81 pediatric patients
The phase 3 CANOPY-HCH-3 trial (NCT06455059) enrolled 81 children aged 3 to younger than 18 years across 23 clinical centers in 9 countries. All participants had genetically confirmed hypochondroplasia and a standing height at least 2 standard deviations below the average for their age and sex (a height Z-score of -2.0 or worse). Before entering the randomized phase, every child completed at least 6 months of height monitoring in the CANOPY HCH-OS observational trial (NCT06212947) to establish an accurate personal baseline growth rate.
Researchers randomly assigned participants in a 1:1 ratio to receive either daily subcutaneous injections of vosoritide (41 children) or a matching placebo injection (40 children) for 52 weeks, with doses calculated according to body weight bands. The primary endpoint measured the difference in annualized growth velocity (AGV) at week 52.
Children in the vosoritide arm achieved a least squares mean AGV change of +1.95 centimeters per year from baseline. Children in the placebo group recorded a least squares mean change of -0.39 centimeters per year. This produced a net growth velocity advantage of 2.33 centimeters per year for vosoritide (95% confidence interval, 1.85 to 2.82; P < .0001).
Key secondary endpoints also demonstrated statistically significant gains favoring vosoritide:
- Standing height increased by an additional 2.35 centimeters over placebo (P < .05).
- Height Z-score improved by 0.39 standard deviations over placebo (P < .05).
- Arm span expanded by 1.03 centimeters more than placebo (P < .05).
Lead study investigator Andrew Dauber, MD, chief of endocrinology at Children’s National in Washington, DC, noted that the observed changes in annualized growth velocity and arm span offer encouraging evidence regarding how pediatric patients respond to daily treatment.
Two secondary endpoints, upper-to-lower body segment ratios and caregiver-reported quality-of-life scores, did not achieve statistical significance under the study’s pre-specified hierarchical testing protocol. Point estimates favored the vosoritide arm, but the study was not statistically powered to prove changes in body proportion or lifestyle metrics within a 52-week window.
Safety outcomes and side effects observed over 52 weeks
Safety monitoring over the 52-week study period showed that vosoritide was well tolerated, matching its known safety history from earlier achondroplasia studies. Adverse events occurred in 87.8% of children in the vosoritide group and 72.5% of children in the placebo group.
Most reported adverse events were mild. Injection-site reactions and minor hypersensitivity reactions occurred slightly more often in children receiving vosoritide, but these reactions were transient and cleared quickly.
Key safety findings across both groups included:
- Zero grade 3 or higher adverse events.
- Zero treatment-related study discontinuations.
- Zero deaths.
Only one serious adverse event occurred during the 52-week trial, consisting of a seizure linked to underlying hypochondroplasia, and that event took place in a child in the placebo group.
Read it with the right caution
While these phase 3 results mark a key clinical milestone, several caveats warrant careful interpretation. First, 52 weeks of growth monitoring cannot confirm whether short-term velocity gains translate into greater final adult height. Long-term follow-up is necessary to determine if early velocity improvements translate into permanent stature increases once growth plates close.
Second, the study excluded children younger than 3 years of age as well as children with milder short stature whose height Z-scores were better than -2.0. Consequently, these data do not clarify whether starting therapy during infancy or in milder cases offers distinct efficacy or safety profiles.
Third, body proportion ratios and caregiver-reported quality-of-life surveys did not show statistically significant separation from placebo over 52 weeks. In previous clinical studies of vosoritide for achondroplasia, measurable improvements in body proportions required 3 full years of continuous daily administration before reaching statistical significance. Parents and clinicians looking at 1-year data should view vosoritide as a long-term growth velocity intervention rather than a rapid corrector of body proportions.
Next steps in regulatory approval and expanding patient groups
Following the publication of the CANOPY-HCH-3 results in NEJM Evidence on September 9, 2026, and presentation at the European Society for Paediatric Endocrinology 2026 Annual Meeting, BioMarin Pharmaceutical initiated formal regulatory steps.
The company submitted a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) seeking to expand vosoritide’s indication to include hypochondroplasia. Parallel regulatory filings are underway with the European Medicines Agency (EMA).
All participants who completed the 52-week phase 3 study have been offered entry into an open-label extension trial to gather multi-year safety and linear growth data. A separate phase 2 study is actively enrolling children with hypochondroplasia under 3 years of age to establish safety and dosing in infants and toddlers. If regulatory authorities grant approval, vosoritide is projected to launch commercially for hypochondroplasia in 2027 as the first targeted disease-modifying treatment for the condition.
Sources:
- Contemporary Pediatrics, “Vosoritide improves growth velocity in children with hypochondroplasia, phase 3 trial shows” (https://www.contemporarypediatrics.com/view/vosoritide-improves-growth-velocity-children-hypochondroplasia-phase-3-trial)
- NEJM Evidence, “Trial of Vosoritide in Children with Hypochondroplasia” (https://evidence.nejm.org/doi/full/10.1056/EVIDoa2600257)
- PubMed / National Library of Medicine, “CANOPY HCH-3 Trial Record” (https://pubmed.ncbi.nlm.nih.gov/42694461)
Disclaimer: This article is for general information only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider about any medical condition or before making health decisions.